small molecule

NORCURON

VECURONIUM BROMIDE

Loss of exclusivity—loss of exclusivity

CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand name	NORCURON
Active ingredient	VECURONIUM BROMIDE
Strength	20MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	INJECTABLE
Route	INJECTION
Modality	Small molecule
FDA approval	January 1992
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.